PetVivo Holdings Inc
OTC:PETV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PetVivo Holdings Inc
Interest Income Expense
PetVivo Holdings Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PetVivo Holdings Inc
OTC:PETV
|
Interest Income Expense
-$1.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
-10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Interest Income Expense
-$369m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Interest Income Expense
$145.4m
|
CAGR 3-Years
68%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Interest Income Expense
-$486m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-24%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Interest Income Expense
-$148m
|
CAGR 3-Years
23%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Interest Income Expense
$365.9m
|
CAGR 3-Years
131%
|
CAGR 5-Years
18%
|
CAGR 10-Years
35%
|
|
PetVivo Holdings Inc
Glance View
PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. The company is headquartered in Edina, Minnesota. The company went IPO on 2012-07-10. The firm is primarily engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The Company’s pipeline product, Kush, is comprised of a patented, gel-like, protein-based biomaterial which may be injected into the afflicted body parts of companion animals suffering from osteoarthritis. Kush’s predecessor formulation completed a Gel-Del-sponsored 145 patient First-in-Man IDE clinical trial using the novel thermoplastic biomaterial as dermal filler for human cosmetic applications.
See Also
What is PetVivo Holdings Inc's Interest Income Expense?
Interest Income Expense
-1.8m
USD
Based on the financial report for Dec 31, 2025, PetVivo Holdings Inc's Interest Income Expense amounts to -1.8m USD.
What is PetVivo Holdings Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-10%
Over the last year, the Interest Income Expense growth was -5 658%.
